A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine

Valdés, Iris; Izquierdo, Alienys; Cobas, Karem; Thao, Phuong; Duc, Hoang Anh; Loc, Hoang Duc; Dung, Le Trung; Lazo, Laura; Suzarte, Edith; Pérez, Yusleidi; Romero, Yaremis; Yaugel, Melyssa; Marcos, Ernesto; Guzmán, María G.; Đạt, Đỗ Tuấn; Hien, Nguyen Dan; Guillén, Gerardo; Gil, Lázaro; Hermida, Lisset

doi:10.1099/jgv.0.001271

Cited by 8 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results demonstrate that animals primed with Tetra DIIIC and later immunized with TV005 developed neutralizing antibodies and protective immune responses against the four DENV serotypes. Additionally, the immune response generated by Tetra DIIIC significantly reduced the viremia produced by the live attenuated viruses (88). Although it has been suggested that all four viruses of TV005 vaccine must produce measurable viremia to ensure the induction of homotypic immunity, there is ample data demonstrating that this formulation induces neutralizing antibodies against the four DENV serotypes in >90% of those vaccinated in the absence of detectable viremia (30, 87, 89).…”

Section: Complementary Prime-boost Immunization Strategies For the Dementioning

confidence: 99%

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

et al. 2019

Self Cite

View full text Add to dashboard Cite

Dengue is one of the most important diseases transmitted by mosquitoes. Dengvaxia®, a vaccine registered in several countries, cannot be administered to non-immune individuals and children younger than 9 years old, due to safety reasons. There are two vaccine candidates in phase 3 efficacy trials, but their registration date is completely unknown at this moment. So, the development of new vaccines or vaccine strategies continues to be a priority for the WHO. This work reviews some complementary prime-boost immunization studies against important human pathogens. Additionally, it reviews the results obtained using this regimen of immunization against dengue virus as a potential alternative approach for finding a safe and efficient vaccine. Finally, the main elements associated with this strategy are also discussed. The generation of new strategies of vaccination against dengue virus, must be directed to reduce the risk of increasing viral load through sub-neutralizing antibodies and it must be also directed to induce a polyfunctional T cell response. Complementary prime-boost immunization strategies could emerge as an interesting approach to induce solid immunity or at least to reduce viral load after natural infection, avoiding severe dengue. Subunit vaccine could be safe and attractive antigens for this strategy, especially proteins including B, and T-cells epitopes for inducing humoral and cellular immune responses, which can play an important role controlling the disease.

show abstract

Section: Complementary Prime-boost Immunization Strategies For the Dementioning

confidence: 99%

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Different immunization strategies such as DNA/ DNA, multi-epitope peptide/multi-epitope peptide, and DNA/multi-epitope peptide were used in BALB/ c mice. Recently, it was reported that the heterologous prime-boost immunization strategy could enhance both humoral and cellular immunity in various laboratory animal models (Kardani et al 2020(Kardani et al , 2016Stachyra et al 2017;Valde ´s et al 2019). Our data demonstrated that groups administrated by the DNA/ B1 nanoparticles induced notably higher levels of IFN-c, IL-5 and Granzyme B as compared to groups receiving the naked DNAs.…”

Section: Discussionmentioning

confidence: 50%

B1 protein: a novel cell penetrating protein for in vitro and in vivo delivery of HIV-1 multi-epitope DNA constructs

et al. 2020

View full text Add to dashboard Cite

Objectives Enhancement of the potential ability of biomacromolecules to cross cell membranes is a critical step for development of effective therapeutic vaccine especially DNA vaccine against human immunodeficiency virus-1 (HIV-1) infection. The supercharged proteins were known as powerful weapons for delivery of different types of cargoes such as DNA and protein. Hence, we applied B1 protein with ? 43 net charges obtained from a single frameshift in the gene encoding enhanced green fluorescent protein (eGFP) for delivery of two multiepitope DNA constructs (nef-vpu-gp160-p24 and nefvif-gp160-p24) in vitro and in vivo for the first time. For this purpose, B1 protein was generated in bacterial expression system under native conditions, and used to interact with both DNA constructs. ResultsOur data indicated that B1 protein (* 27 kDa) was able to form a stable nanoparticle (* 80-110 nm) with both DNA constructs at nitrogen: phosphate (N: P) ratio of 1:1. Moreover, the transfection efficiency of B1 protein for DNA delivery into HEK-293T cell line indicated that the cellular uptake of nef-vif-gp160-p24 DNA/ B1 and nef-vpu-gp160-p24 DNA/ B1 nanoparticles was about 32-35% with lower intensity as compared to TurboFect commercial reagent. On the other hand, immunization of BALB/c mice with different modalities demonstrated that B1 protein could enhance the levels of antibody, IFN-gamma and Granzyme B eliciting potent and strong Th1-directed cellular immunity. Conclusion Generally, our findings showed the potency of B1 protein as a promising gene delivery system to improve an effective therapeutic vaccine against HIV-1 infection.

show abstract

“…Heterologous prime-boost strategies have been in development for some years now against many viral pathogens, including DENV and Japanese encephalitis virus (JEV) [52][53][54][55][56] . These strategies include the use of inactivated viruses, protein or subunit antigens, DNA that codes for a viral protein, chimeric viruses, and attenuated viruses in various combinations and schedules, and often produce greater and/or more balanced immune responses as compared to vaccination with one component alone or a homologous primeboost regimen.…”

Section: Discussionmentioning

confidence: 99%

Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques

et al. 2021

View full text Add to dashboard Cite

Antibody-dependent enhancement (ADE) is suspected to influence dengue virus (DENV) infection, but the role ADE plays in vaccination strategies incorporating live attenuated virus components is less clear. Using a heterologous prime-boost strategy in rhesus macaques, we examine the effect of priming with DENV purified inactivated vaccines (PIVs) on a tetravalent live attenuated vaccine (LAV). Sera exhibited low-level neutralizing antibodies (NAb) post PIV priming, yet moderate to high in vitro ADE activity. Following LAV administration, the PIV primed groups exhibited DENV-2 LAV peak viremias up to 1,176-fold higher than the mock primed group, and peak viremia correlated with in vitro ADE. Furthermore, PIV primed groups had more balanced and higher DENV-1–4 NAb seroconversion and titers than the mock primed group following LAV administration. These results have implications for the development of effective DENV vaccine prime-boost strategies and for our understanding of the role played by ADE in modulating DENV replication.

show abstract

A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine

Cited by 8 publications

References 39 publications

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

B1 protein: a novel cell penetrating protein for in vitro and in vivo delivery of HIV-1 multi-epitope DNA constructs

Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques

Contact Info

Product

Resources

About